The androgen receptor in bladder cancer

Area of Science:

• Oncology
• Urology
• Endocrinology

Background:

• Bladder cancer is a prevalent malignancy globally, exhibiting significant sex-based incidence differences.
• Emerging research suggests the androgen receptor (AR) plays a role in bladder cancer development, progression, and recurrence, potentially explaining observed sex disparities.
• Understanding the androgen-AR signaling pathway is crucial for developing effective bladder cancer treatments.

Purpose of the Study:

• To explore the role of androgen receptor (AR) signaling in bladder cancer.
• To investigate the potential of targeting AR as a therapeutic strategy for bladder cancer.
• To highlight the implications of novel AR discoveries for bladder cancer treatment.

Main Methods:

• Review of current scientific literature on bladder cancer and androgen receptor signaling.
• Analysis of emerging evidence on AR's role in bladder cancer pathogenesis and sex differences.
• Examination of the therapeutic potential of targeting AR and related pathways.

Main Results:

• The androgen receptor (AR) is implicated in promoting bladder cancer development, progression, and recurrence.
• Targeting androgen-AR signaling demonstrates promise for suppressing bladder cancer progression.
• Identification of a novel membrane AR and AR-regulated non-coding RNAs offers new therapeutic avenues.

Conclusions:

• Targeting androgen-AR signaling is a promising therapeutic strategy for bladder cancer, potentially mitigating sex-based incidence differences.
• Further research and clinical trials focusing on AR-targeted therapies are essential for advancing bladder cancer treatment.
• Novel discoveries, including membrane AR and non-coding RNAs, hold significant implications for future bladder cancer therapeutic development.